201 related articles for article (PubMed ID: 36674793)
1. Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment.
Wolk K; Wilsmann-Theis D; Witte K; Brembach TC; Kromer C; Gerdes S; Ghoreschi K; Reich K; Mössner R; Sabat R
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674793
[TBL] [Abstract][Full Text] [Related]
2. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Wilsmann-Theis D; Kromer C; Gerdes S; Linker C; Magnolo N; Sabat R; Reich K; Mössner R
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2045-2050. PubMed ID: 34077577
[TBL] [Abstract][Full Text] [Related]
3. Interleukin (IL)-8 and IL-36γ but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis.
Xiaoling Y; Chao W; Wenming W; Feng L; Hongzhong J
Clin Exp Dermatol; 2019 Jan; 44(1):52-57. PubMed ID: 29896852
[TBL] [Abstract][Full Text] [Related]
4. Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study.
Kato N; Takama H; Ando Y; Yanagishita T; Ohshima Y; Ohashi W; Akiyama M; Watanabe D
Int J Dermatol; 2021 May; 60(5):570-578. PubMed ID: 33454961
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations.
Freitas E; Rodrigues MA; Torres T
Clin Cosmet Investig Dermatol; 2020; 13():561-578. PubMed ID: 32884319
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of lipocalin 2 in palmoplantar pustular psoriasis.
Wolk K; Frambach Y; Jacobi A; Wilsmann-Theis D; Phillipp S; Witte-Händel E; Wenzel J; Mössner R; Sabat R
J Dermatol Sci; 2018 Apr; 90(1):68-74. PubMed ID: 29395573
[TBL] [Abstract][Full Text] [Related]
7. Dietary habits in Japanese patients with palmoplantar pustulosis.
Serizawa N; Okazaki S; Otsuka Y; Koto M; Okabe K; Ito M; Morita T; Hoashi T; Saeki H; Abe N; Mori M; Okubo Y; Yano Y; Mitsui H; Kanda N
J Dermatol; 2021 Mar; 48(3):366-375. PubMed ID: 33404125
[TBL] [Abstract][Full Text] [Related]
8. Detection rate of pustules in palmoplantar pustulosis with dermoscopy.
Nakanishi T; Kokubu H; Fujimoto N; Tanaka T
J Dermatol; 2022 Feb; 49(2):299-302. PubMed ID: 34723401
[TBL] [Abstract][Full Text] [Related]
9. Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism.
Murakami M; Terui T
J Dermatol Sci; 2020 Apr; 98(1):13-19. PubMed ID: 32201085
[TBL] [Abstract][Full Text] [Related]
10. Extra-palmoplantar lesions associated with palmoplantar pustulosis.
Yamamoto T
J Eur Acad Dermatol Venereol; 2009 Nov; 23(11):1227-32. PubMed ID: 19453807
[TBL] [Abstract][Full Text] [Related]
11. Refractory palmoplantar pustulosis succesfully treated with apremilast.
Carrascosa de Lome R; Conde Montero E; de la Cueva Dobao P
Dermatol Ther; 2020 Mar; 33(2):e13230. PubMed ID: 31981290
[TBL] [Abstract][Full Text] [Related]
12. Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders.
Liang Y; Xing X; Beamer MA; Swindell WR; Sarkar MK; Roberts LW; Voorhees JJ; Kahlenberg JM; Harms PW; Johnston A; Gudjonsson JE
J Allergy Clin Immunol; 2017 Apr; 139(4):1217-1227. PubMed ID: 27884600
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
[TBL] [Abstract][Full Text] [Related]
14. Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis.
Hagforsen E; Hedstrand H; Nyberg F; Michaëlsson G
Br J Dermatol; 2010 Sep; 163(3):572-9. PubMed ID: 20426778
[TBL] [Abstract][Full Text] [Related]
15. DiGeorge syndrome presenting with palmoplantar pustules: Comparative analysis of serum IL-22, NETs and IL-8 with usual palmoplantar pustulosis.
Ogura Y; Kondo S; Suzuki T; Otsuka M; Inuzuka M; Honda T; Tokura Y
J Dermatol; 2024 May; 51(5):731-734. PubMed ID: 38111339
[TBL] [Abstract][Full Text] [Related]
16. Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis.
Murakami M; Kaneko T; Nakatsuji T; Kameda K; Okazaki H; Dai X; Hanakawa Y; Tohyama M; Ishida-Yamamoto A; Sayama K
PLoS One; 2014; 9(10):e110677. PubMed ID: 25330301
[TBL] [Abstract][Full Text] [Related]
17. Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study.
Okubo Y; Terui T; Kobayashi S; Sano S; Morita A; Imafuku S; Tada Y; Abe M; Yaguchi M; Kimura T; Shimauchi J; Zhang W; Amouzadeh H; Murakami M
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38896381
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in palmoplantar pustulosis.
Brunasso AMG; Massone C
Fac Rev; 2021; 10():62. PubMed ID: 34409425
[TBL] [Abstract][Full Text] [Related]
19. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
[TBL] [Abstract][Full Text] [Related]
20. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
Menter A; Van Voorhees AS; Hsu S
Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
